Overview
Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea
Status:
Completed
Completed
Trial end date:
2012-04-01
2012-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This 24-weeks study will to compare the glycemic efficacy and safety of sitagliptin with pioglitazone in patients with type 2 diabetes who had inadequate glycemic control despite dual therapy with metformin and a sulfonylurea.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Sung-Chen LiuCollaborator:
Mackay Memorial HospitalTreatments:
Metformin
Pioglitazone
Sitagliptin Phosphate
Criteria
Inclusion Criteria:- Type 2 diabetes patients who were treated with stable doses of sulfonylurea and
metformin to their half maximally dose (sulfonylureas > half maximal dose, and
metformin > 1500 mg/d) for > 10 weeks
- > 20 years old
- A1C: > 7.0 % and < 11%
Exclusion Criteria:
- Insulin use within 12 weeks of the screening visit
- Any contraindications for use of sitagliptin or pioglitazone, impaired renal function
(serum creatinine > 1.4 mg/dl), alanine aminotransferase or aspartate aminotransferase
levels > 2.5 times the upper limit of normal
- Current or prepare to pregnancy and lactation